NCT03096041

Brief Summary

Auriculotherapy is a complementary medicine, with few side effects, without contraindication, inexpensive and not very restrictive.Its efficacy has been found in several tests especially for the treatment of intraoperative pain. It remains more controversial in other indications. Evaluation of the value of auriculotherapy is often difficult because of the methodological limitations of the trials conducted. In the daily practice, the auriculotherapy is proposed to improve the articular pains of patients treated by AA. This Phase III study aims at validate this approach.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
197

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2017

Longer than P75 for not_applicable

Geographic Reach
1 country

7 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 20, 2017

Completed
10 days until next milestone

First Posted

Study publicly available on registry

March 30, 2017

Completed
3 months until next milestone

Study Start

First participant enrolled

July 5, 2017

Completed
8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 7, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 7, 2025

Completed
Last Updated

September 12, 2025

Status Verified

September 1, 2025

Enrollment Period

8 years

First QC Date

March 20, 2017

Last Update Submit

September 8, 2025

Conditions

Keywords

auriculotherapyaromatase inhibitorsadjuvant treatment

Outcome Measures

Primary Outcomes (1)

  • Decrease in the overall pain score

    The proportion of patients with a 2-point or greater decrease in the overall pain

    3 months after auriculotherapy initiation

Study Arms (2)

Experimental arm

EXPERIMENTAL

Auriculotherapy for analgesic use

Device: Auriculotherapy for analgesic use

Controle arm

PLACEBO COMPARATOR

Placebo auriculotherapy

Device: Placebo auriculotherapy

Interventions

The ASP will be applied to specific pain points

Experimental arm

The ASP will be applied to placebo points (not specific to pain)

Controle arm

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient over 18 years of age
  • Patients with anti-aromatases in adjuvant treatment of breast cancer
  • Menopausal women
  • Treatment with aromatase inhibitors (anti-aromatase, AA) initiated for more than 3 months. In the case of a change in anti-aromatase, the last treatment must be started for more than 3 months.
  • Musculoskeletal pain appearing or increased under AA:
  • Overall pain score of QCD ≥3 (on a scale of 0 to 10)
  • Pain on at least 2 sites
  • Pain for at least 3 months
  • History of radiotherapy and / or adjuvant chemotherapy authorized
  • Patients may have received tamoxifen
  • Patient affiliated to a social security system
  • Patient mastering the French language and able to complete the evaluation questionnaires
  • Free and Informed Consent

You may not qualify if:

  • Patients who have already undergone treatment in auriculotherapy for the same indication
  • Patient benefiting at the same time from a PNCAVT (acupuncture or homeopathy) for musculoskeletal pain
  • Wearing hearing aids hindering the placement of semi-permanent needles (ASP)
  • Wearing of a valve prosthesis
  • Patient under guardianship or unable to give informed consent
  • Patient unable to undergo medical follow-up for geographical, social or psychopathological reasons

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (7)

Centre François Baclesse

Caen, 14000, France

Location

Hôpital Privé Paul d'Egine

Champigny-sur-Marne, France

Location

Hôpital Cognac-Jay - Forcilles

Férolles-Attilly, France

Location

CHU Grenoble

Grenoble, France

Location

Centre Oscar Lambret

Lille, France

Location

Groupe Hospitalier Paris St Joseph

Paris, France

Location

IGR

Villejuif, France

Location

MeSH Terms

Conditions

Musculoskeletal PainBreast Neoplasms

Interventions

Auriculotherapy

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsNeoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Complementary TherapiesTherapeutics

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
Single blind
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 20, 2017

First Posted

March 30, 2017

Study Start

July 5, 2017

Primary Completion

July 7, 2025

Study Completion

July 7, 2025

Last Updated

September 12, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Locations